Coagulation factor–phospholipid complex

Coagulation factors are a group of plasma proteins, mostly serine proteases, that collectively drive the blood coagulation (clotting) cascade leading to thrombin and fibrin formation[2][6]. Many of these factors, such as factor VIII, IX, V, and X, require assembly on a phospholipid surface—typically the exposed inner leaflet phospholipids of activated platelets (notably phosphatidylserine, PS, and phosphatidylethanolamine, PE)[3][4][5][6]. These negatively charged phospholipid surfaces greatly increase the catalytic efficiency and specificity of coagulation by localizing factors and orienting them properly—examples include the intrinsic tenase complex (factor VIIIa:IXa) and prothrombinase complex (factor Va:Xa). Calcium ions are essential connectors, binding gamma-carboxyglutamic acid (Gla) domains of coagulation factors to the anionic phospholipid headgroups[2][3][6]. While "coagulation factor–phospholipid complex" is not itself a single molecular entity or canonical therapeutic target, this supramolecular assembly is critical in hemostasis, and its disruption or inhibition is the basis of several antithrombotic therapies[2][5][6]. Defects in factor–phospholipid interactions underlie several bleeding disorders (e.g., hemophilia), while hyperactivation or improper exposure can contribute to thrombosis. **Note:** Coagulation factors and phospholipid surfaces refer to multiple components and their interaction; they are not a single defined molecular entity or conventional drug target, hence this entry is marked as “is_incorrect: true”[2][3][6].

Other names

Coagulation factors on phospholipid surfacesBlood clotting factor–membrane complexesCoagulation enzyme–phospholipid complexes

Inhibition of coagulation factor activation (e.g., by VKORC1 inhibitors like warfarin) - Antagonizing assembly of enzyme–phospholipid complexes (e.g., heparin enhancing antithrombin effect) - Direct inhibition of factor activity (e.g., direct Xa inhibitors)